多态变异DRD2、DRD3和DRD4与青少年急性精神病发作抗精神病药物的早期疗效和安全性有关

Clinical pharmacology and therapy Pub Date : 2021-06-01 DOI:10.32756/0869-5490-2021-2-75-80

D. V. Ivaschenko, L. Fedina, D.A. Yudelievich, N. Buromskaya, P. V. Shimanov, R. V. Deitsch, I. V. Dorina, K. Akmalova, A. Kachanova, E. Grishina, L. Savchenko, Y. Shevchenko, D. Sychev

{"title":"多态变异DRD2、DRD3和DRD4与青少年急性精神病发作抗精神病药物的早期疗效和安全性有关","authors":"D. V. Ivaschenko, L. Fedina, D.A. Yudelievich, N. Buromskaya, P. V. Shimanov, R. V. Deitsch, I. V. Dorina, K. Akmalova, A. Kachanova, E. Grishina, L. Savchenko, Y. Shevchenko, D. Sychev","doi":"10.32756/0869-5490-2021-2-75-80","DOIUrl":null,"url":null,"abstract":"The prospective observational study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission. Patients were followed up for 14 days. All patients received an antipsychotic as their main therapy. The following scales were used to assess the efficacy and safety of therapy on day 14: CGAS, PANSS, CGI-S, CGI-I, UKU SERS, SAS, BARS. The determination of polymorphic variants of DRD2 (rs1800497, C>T), DRD3 (rs6280, C>T), DRD3 (rs324026, C>T), and DRD4 (rs1800955, C>T) genes was performed by real-time polymerase chain reaction (PCR).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"236 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The polymorphic variants DRD2, DRD3, and DRD4 are associated with early efficacy and safety of antipsychotics in adolescents with an acute psychotic episode\",\"authors\":\"D. V. Ivaschenko, L. Fedina, D.A. Yudelievich, N. Buromskaya, P. V. Shimanov, R. V. Deitsch, I. V. Dorina, K. Akmalova, A. Kachanova, E. Grishina, L. Savchenko, Y. Shevchenko, D. Sychev\",\"doi\":\"10.32756/0869-5490-2021-2-75-80\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The prospective observational study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission. Patients were followed up for 14 days. All patients received an antipsychotic as their main therapy. The following scales were used to assess the efficacy and safety of therapy on day 14: CGAS, PANSS, CGI-S, CGI-I, UKU SERS, SAS, BARS. The determination of polymorphic variants of DRD2 (rs1800497, C>T), DRD3 (rs6280, C>T), DRD3 (rs324026, C>T), and DRD4 (rs1800955, C>T) genes was performed by real-time polymerase chain reaction (PCR).\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"236 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2021-2-75-80\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2021-2-75-80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

这项前瞻性观察性研究包括101名在入院时被诊断为急性多态精神障碍的青少年。随访14 d。所有患者均以抗精神病药物作为主要治疗手段。采用以下量表评估第14天治疗的有效性和安全性:CGAS、PANSS、CGI-S、CGI-I、UKU SERS、SAS、BARS。采用实时聚合酶链反应(real-time polymerase chain reaction, PCR)检测DRD2 (rs1800497, C>T)、DRD3 (rs6280, C>T)、DRD3 (rs324026, C>T)和DRD4 (rs1800955, C>T)基因多态性变异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The polymorphic variants DRD2, DRD3, and DRD4 are associated with early efficacy and safety of antipsychotics in adolescents with an acute psychotic episode

The prospective observational study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission. Patients were followed up for 14 days. All patients received an antipsychotic as their main therapy. The following scales were used to assess the efficacy and safety of therapy on day 14: CGAS, PANSS, CGI-S, CGI-I, UKU SERS, SAS, BARS. The determination of polymorphic variants of DRD2 (rs1800497, C>T), DRD3 (rs6280, C>T), DRD3 (rs324026, C>T), and DRD4 (rs1800955, C>T) genes was performed by real-time polymerase chain reaction (PCR).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical pharmacology and therapy

自引率

0.00%

发文量